Pfizer lifted its full-year 2026 forecast after a stronger third quarter. Adjusted earnings reached 87 cents per share, well above the 73 cents analysts expected. Revenue climbed to $16.58 billion against a $15.87 billion consensus. The drugmaker now expects $62 billion to $64 billion in 2026 revenue and adjusted earnings of $2.95 to $3.05 per share.
What happened: a guidance raise with a cushion
The new midpoint of $3.00 per share is ten cents higher than the prior forecast. That increase absorbs a charge of ten cents per share, roughly $650 million, tied to Pfizer’s investment in Innovent Biologics.
Shares have gained about 25 percent this year and closed near $29.60 in recent trading.
Key numbers from the quarter
| Metric | Q3 2026 result | Reference point |
|---|---|---|
| Adjusted EPS | $0.87 | $0.73 consensus |
| Revenue | $16.58 billion | $15.87 billion consensus |
| Non-COVID product growth | 7 percent operational | Company reporting |
| Launched product revenue | $3.8 billion, up 32 percent | Padcev $391 million, Nurtec $244 million, Lorbrena $205 million |
| Adjusted gross margin | 77 percent | Company reporting |
| FY 2026 revenue guidance | $62 to $64 billion | Prior: $60.5 to $62.5 billion |
| FY 2026 adjusted EPS | $2.95 to $3.05 | Prior: $2.80 to $3.00 |
Pfizer is also building a lower cost base for the rest of the decade. Management pointed to $7.2 billion in savings by the end of 2026 and another $2.5 billion through 2029. A new chief financial officer, Cecile Guegan, arrives as those programs continue.
What the dividend looks like now
The board declared a 43-cent quarterly dividend on October 6, payable December 7 to holders of record on November 6. It is the 352nd consecutive quarterly dividend in company history. The next payment lands on December 7 for investors who owned shares by the November 6 record date. At a share price near $29.60, the $1.72 annualized payout yields about 5.8 percent.
The payout has held flat since early 2025, when the board raised it 2.4 percent from 42 cents. Against the new guidance, the dividend consumes roughly 56 to 58 percent of adjusted earnings. A $100,000 position generates about $5,800 in annual dividend income at today’s yield.
What to watch
Cash flow is the number to track. In 2025, free cash flow of about $9.1 billion fell short of the $9.8 billion paid in dividends, and first-half 2026 free cash flow was thin. Patent expirations loom late in the decade; the 2028 earnings consensus sits near $2.48 per share. Management expects roughly $4 billion of COVID product revenue this year, a figure that shrinks as demand normalizes.
Bottom line
Pfizer offers one of the highest yields among large pharmaceutical names, supported by a raised 2026 outlook. The dividend looks secure on an earnings basis but depends on cash flow recovery. Income investors should size the position with the patent cliff in view.
Common mistakes income investors make
Chasing the headline yield without checking cash flow coverage is the most common error. Treating a flat dividend as a warning of a cut is another. The payout has held steady for two years while the earnings base beneath it grows. A third mistake is ignoring the patent cliff, which analysts already price into 2028 estimates.
Investors following this story may also want to read our dividend growth coverage, dividend growth coverage, dividend growth coverage, and dividend growth coverage.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
